Trille Kjaer1, Christoffer Johansen2,3, Elo Andersen4, Randi Karlsen2, Anni Linnet Nielsen4, Kirsten Frederiksen5, Mikael Rørth3, Susanne Oksbjerg Dalton2. 1. Survivorship, Danish Cancer Society Research Center, Strandboulevarden 49, 2100, Copenhagen, Denmark. trille@cancer.dk. 2. Survivorship, Danish Cancer Society Research Center, Strandboulevarden 49, 2100, Copenhagen, Denmark. 3. Department of Oncology, Rigshospitalet, Blegdamsvej 9, 2100, Copenhagen, Denmark. 4. Department of Oncology, Herlev Hospital, Herlev Ringvej 75, 2730, Herlev, Denmark. 5. Department of Statistics, Bioinformatics and Registry, Danish Cancer Society Research Center, Strandboulevarden 49, 2100, Copenhagen, Denmark.
Abstract
PURPOSE: This study seeks to assess the differences in disease and socioeconomic characteristics, late effects and long-term quality of life (QoL) after head-and-neck cancer (HNC) among participants and non-participants. METHODS: Five hundred sixty recurrence-free survivors treated for HNC at least 6 months previously were invited to participate in a repeated measure, controlled intervention study of computerized Patient Reported Outcome (PRO), which is provided to treating physicians at the point of care. Two hundred sixty-six consented to participate, and 292 declined; of those who declined, 103 filled in the baseline questionnaire. Late effects and QoL were evaluated on the EORTC QLQ C-30 and EORTC QLQ H&N35 and HADS questionnaires, and an empirically derived symptom list was prepared with hospital clinicians. RESULTS: Participants were younger, had a higher educational level, were more likely to cohabit, less likely to smoke, used less alcohol and were more likely to have HPV than those who declined but did not differ by gender, cancer site, stage or time since diagnosis. Participants reported significantly better QoL and functioning and less severe symptoms than those who declined participation other than filling in the baseline questionnaire. CONCLUSIONS: Late symptoms are common in HNC survivors. A wide diversity of self-reported late effects was found in this trial with participants significantly less affected than non-participants. IMPLICATIONS FOR CANCER SURVIVORS: Generalizable data on non-participation may aid in the interpretation of studies on HNC survivors in general and may have relevance for targeting recruitment and maintenance in rehabilitation and follow-up care, outside clinical trials.
PURPOSE: This study seeks to assess the differences in disease and socioeconomic characteristics, late effects and long-term quality of life (QoL) after head-and-neck cancer (HNC) among participants and non-participants. METHODS: Five hundred sixty recurrence-free survivors treated for HNC at least 6 months previously were invited to participate in a repeated measure, controlled intervention study of computerized Patient Reported Outcome (PRO), which is provided to treating physicians at the point of care. Two hundred sixty-six consented to participate, and 292 declined; of those who declined, 103 filled in the baseline questionnaire. Late effects and QoL were evaluated on the EORTC QLQ C-30 and EORTC QLQ H&N35 and HADS questionnaires, and an empirically derived symptom list was prepared with hospital clinicians. RESULTS:Participants were younger, had a higher educational level, were more likely to cohabit, less likely to smoke, used less alcohol and were more likely to have HPV than those who declined but did not differ by gender, cancer site, stage or time since diagnosis. Participants reported significantly better QoL and functioning and less severe symptoms than those who declined participation other than filling in the baseline questionnaire. CONCLUSIONS: Late symptoms are common in HNC survivors. A wide diversity of self-reported late effects was found in this trial with participants significantly less affected than non-participants. IMPLICATIONS FOR CANCER SURVIVORS: Generalizable data on non-participation may aid in the interpretation of studies on HNC survivors in general and may have relevance for targeting recruitment and maintenance in rehabilitation and follow-up care, outside clinical trials.
Entities:
Keywords:
Cancer survivorship; Head-and-neck cancer; Intervention study; Late effect; Non-participant; Patient-reported outcome
Authors: Mollie W Howerton; M Chris Gibbons; Charles R Baffi; Tiffany L Gary; Gabriel Y Lai; Shari Bolen; Jon Tilburt; Teerath Peter Tanpitukpongse; Renee F Wilson; Neil R Powe; Eric B Bass; Jean G Ford Journal: Cancer Date: 2007-02-01 Impact factor: 6.860
Authors: Jean G Ford; Mollie W Howerton; Gabriel Y Lai; Tiffany L Gary; Shari Bolen; M Chris Gibbons; Jon Tilburt; Charles Baffi; Teerath Peter Tanpitukpongse; Renee F Wilson; Neil R Powe; Eric B Bass Journal: Cancer Date: 2008-01-15 Impact factor: 6.860
Authors: Cornelia M Ruland; Harald H Holte; Jo Røislien; Cathy Heaven; Glenys A Hamilton; Jørn Kristiansen; Heidi Sandbaek; Stein O Kvaløy; Line Hasund; Misoo C Ellison Journal: J Am Med Inform Assoc Date: 2010 Jul-Aug Impact factor: 4.497
Authors: Johannes A Langendijk; Patricia Doornaert; Irma M Verdonck-de Leeuw; Charles R Leemans; Neil K Aaronson; Ben J Slotman Journal: J Clin Oncol Date: 2008-08-01 Impact factor: 44.544
Authors: Galina Velikova; Laura Booth; Adam B Smith; Paul M Brown; Pamela Lynch; Julia M Brown; Peter J Selby Journal: J Clin Oncol Date: 2004-02-15 Impact factor: 44.544
Authors: Karen L Syrjala; Jean C Yi; Samantha B Artherholt; Joan M Romano; Marie-Laure Crouch; Allison S Fiscalini; Mark T Hegel; Mary E D Flowers; Paul J Martin; Wendy M Leisenring Journal: J Cancer Surviv Date: 2018-05-05 Impact factor: 4.442
Authors: Belle H de Rooij; Nicole P M Ezendam; Floortje Mols; Pauline A J Vissers; Melissa S Y Thong; Carla C P Vlooswijk; Simone Oerlemans; Olga Husson; Nicole J E Horevoorts; Lonneke V van de Poll-Franse Journal: Qual Life Res Date: 2018-08-30 Impact factor: 4.147
Authors: Imogen Ramsey; Belle H de Rooij; Floortje Mols; Nadia Corsini; Nicole J E Horevoorts; Marion Eckert; Lonneke V van de Poll-Franse Journal: J Cancer Surviv Date: 2019-09-06 Impact factor: 4.442